脾胃培源丸联合艾灸治疗慢性萎缩性胃炎脾胃虚弱证的临床研究

R259; 目的 观察脾胃培源丸联合艾灸治疗慢性萎缩性胃炎脾胃虚弱证患者的临床疗效及其机制.方法 收集2022 年6 月—2023 年12 月就诊于安徽中医药大学第二附属医院脾胃科的慢性萎缩性胃炎脾胃虚弱证患者,将符合纳排标准的96 例患者采用随机数字表法分为对照组、中药组及联合组,每组32 例(每组各脱落2 例).对照组患者给予瑞巴派特片联合叶酸片治疗(均 3 次/d),中药组患者予脾胃培源丸(8g,3 次/d),联合组在中药组基础上加艾灸(1 次/d),连续12 周.观察3 组患者治疗前后胃黏膜萎缩情况;进行胃黏膜病理评分;患者报告结局(PRO)量表评价患者身心状态、生活质量;酶联免疫吸附...

Full description

Saved in:
Bibliographic Details
Published in北京中医药大学学报 Vol. 48; no. 2; pp. 280 - 290
Main Authors 吴凯瑞, 叶宇, 裴蓓, 宋标, 张艺, 李婷婷, 杨琦, 刘云, 李学军
Format Journal Article
LanguageChinese
Published 安徽中医药大学研究生院 合肥 230012%安徽中医药大学第二附属医院脾胃科 01.02.2025
Subjects
Online AccessGet full text

Cover

Loading…
Abstract R259; 目的 观察脾胃培源丸联合艾灸治疗慢性萎缩性胃炎脾胃虚弱证患者的临床疗效及其机制.方法 收集2022 年6 月—2023 年12 月就诊于安徽中医药大学第二附属医院脾胃科的慢性萎缩性胃炎脾胃虚弱证患者,将符合纳排标准的96 例患者采用随机数字表法分为对照组、中药组及联合组,每组32 例(每组各脱落2 例).对照组患者给予瑞巴派特片联合叶酸片治疗(均 3 次/d),中药组患者予脾胃培源丸(8g,3 次/d),联合组在中药组基础上加艾灸(1 次/d),连续12 周.观察3 组患者治疗前后胃黏膜萎缩情况;进行胃黏膜病理评分;患者报告结局(PRO)量表评价患者身心状态、生活质量;酶联免疫吸附测定法检测各组患者血清肿瘤坏死因子(TNF)-α、白细胞介素(IL)-1β、IL-4、IL-10、IL-37、转化生长因子(TGF)-β含量;实时荧光定量PCR法检测各组患者信号转导和转录激活因子 3(STAT3)、哺乳动物雷帕霉素靶蛋白(mTOR)mRNA 表达;蛋白质印迹法检测STAT3/mTOR信号通路相关蛋白表达,记录并比较药物不良反应与不良事件.结果 3 组患者年龄、性别、病程、消化道肿瘤家族史、饮酒史、体质量指数差异无统计学意义.对照组、中药组与联合组治疗胃黏膜萎缩总有效率分别为66.67%(20/30)、86.67%(26/30)、90.00%(27/30)(P<0.05).与治疗前比较,各组患者治疗后胃黏膜病理评分、PRO量表评分降低,TNF-α、IL-1β、IL-37、TGF-β含量降低,STAT3、mTOR mRNA相对表达量及STAT3、p-STAT3、mTOR、p-mTOR蛋白相对表达量均降低(P<0.05),IL-4、IL-10 含量均升高(P<0.05).治疗后,与对照组比较,中药组与联合组胃黏膜病理评分、PRO 量表评分,TNF-α、IL-1β、IL-37、TGF-β 含量,STAT3、mTOR mRNA 相对表达量及STAT3、p-STAT3、mTOR、p-mTOR蛋白相对表达量均降低(P<0.05),IL-4、IL-10 含量均升高(P<0.05).治疗后,与中药组比较,联合组STAT3、mTOR mRNA 及STAT3、p-STAT3、mTOR、p-mTOR蛋白相对表达量均降低(P<0.05).结论 脾胃培源丸联合艾灸可能通过抑制STAT3/mTOR信号通路异常活化,调控机体炎症机制,上调
AbstractList R259; 目的 观察脾胃培源丸联合艾灸治疗慢性萎缩性胃炎脾胃虚弱证患者的临床疗效及其机制.方法 收集2022 年6 月—2023 年12 月就诊于安徽中医药大学第二附属医院脾胃科的慢性萎缩性胃炎脾胃虚弱证患者,将符合纳排标准的96 例患者采用随机数字表法分为对照组、中药组及联合组,每组32 例(每组各脱落2 例).对照组患者给予瑞巴派特片联合叶酸片治疗(均 3 次/d),中药组患者予脾胃培源丸(8g,3 次/d),联合组在中药组基础上加艾灸(1 次/d),连续12 周.观察3 组患者治疗前后胃黏膜萎缩情况;进行胃黏膜病理评分;患者报告结局(PRO)量表评价患者身心状态、生活质量;酶联免疫吸附测定法检测各组患者血清肿瘤坏死因子(TNF)-α、白细胞介素(IL)-1β、IL-4、IL-10、IL-37、转化生长因子(TGF)-β含量;实时荧光定量PCR法检测各组患者信号转导和转录激活因子 3(STAT3)、哺乳动物雷帕霉素靶蛋白(mTOR)mRNA 表达;蛋白质印迹法检测STAT3/mTOR信号通路相关蛋白表达,记录并比较药物不良反应与不良事件.结果 3 组患者年龄、性别、病程、消化道肿瘤家族史、饮酒史、体质量指数差异无统计学意义.对照组、中药组与联合组治疗胃黏膜萎缩总有效率分别为66.67%(20/30)、86.67%(26/30)、90.00%(27/30)(P<0.05).与治疗前比较,各组患者治疗后胃黏膜病理评分、PRO量表评分降低,TNF-α、IL-1β、IL-37、TGF-β含量降低,STAT3、mTOR mRNA相对表达量及STAT3、p-STAT3、mTOR、p-mTOR蛋白相对表达量均降低(P<0.05),IL-4、IL-10 含量均升高(P<0.05).治疗后,与对照组比较,中药组与联合组胃黏膜病理评分、PRO 量表评分,TNF-α、IL-1β、IL-37、TGF-β 含量,STAT3、mTOR mRNA 相对表达量及STAT3、p-STAT3、mTOR、p-mTOR蛋白相对表达量均降低(P<0.05),IL-4、IL-10 含量均升高(P<0.05).治疗后,与中药组比较,联合组STAT3、mTOR mRNA 及STAT3、p-STAT3、mTOR、p-mTOR蛋白相对表达量均降低(P<0.05).结论 脾胃培源丸联合艾灸可能通过抑制STAT3/mTOR信号通路异常活化,调控机体炎症机制,上调
Abstract_FL Objective To determine the clinical efficacy and mechanism of Piwei Peiyuan Pill(PPP)combined with moxibustion for treating patients with chronic atrophic gastritis(CAG)with spleen and stomach weakness syndrome.Methods Ninety-six CAG patients with spleen and stomach weakness syndrome who met the inclusion and exclusion criteria were enrolled at the Department of Spleen and Stomach Diseases of the Second Affiliated Hospital of Anhui University of Chinese Medicine from June 2022 to December 2023.The patients were randomly divided into a control,a Chinese medicine,and a combined group using a random number table method,with 32 cases in each group(two cases per group were excluded).The control group was treated with rabeprazole combined with folic acid tablets(both thrice daily),the Chinese medicine group was treated with PPP(8 g,thrice daily),and the combined group was treated with moxa stick moxibustion(once daily)on the basis of the Chinese medicine group for 12 consecutive weeks.Gastric mucosa atrophy in the three groups was observed before and after treatment.The gastric mucosal pathological score was evaluated.The Patient Reported Outcome(PRO)scale was used to evaluate the patients' physical and mental health status and quality of life.An enzyme-linked immunosorbent assay was used to detect serum tumor necrosis factor(TNF)-α,interleukin(IL)-1β,IL-4,IL-10,IL-37,and transforming growth factor(TGF)-β levels in each group.Real-time fluorescence PCR was used to detect the relative expression levels of signal transducer and activator of transcription 3(STAT3)and mammalian target of rapamycin(mTOR)mRNA in each group.Western blotting was used to detect the relative expression levels of proteins related to the STAT3/mTOR signaling pathway,and the adverse drug reactions and events were recorded and compared.Results There was no statistical difference in age,gender,disease duration,family history of gastrointestinal tumors,alcohol consumption history,and body mass index among the three groups of patients.The total therapeutic efficacy rates of the control,Chinese medicine,and combined groups in treating gastric mucosal atrophy were 66.67%(20/30),86.67%(26/30),and 90.00%(27/30),respectively(P<0.05).Compared to before treatment,the pathological and PRO scale scores of gastric mucosa in each group decreased after treatment,and TNF-α,IL-1β,IL-37,and TGF-β levels decreased.The relative STAT3 and mTOR mRNA expression levels,as well as the relative STAT3,p-STAT3,mTOR,and p-mTOR protein expression levels decreased(P<0.05),whereas the IL-4 and IL-10 levels increased(P<0.05).After treatment,compared to the control group,the pathological score of gastric mucosa,PRO scale score,TNF-α,IL-1β,IL-37,TGF-β content,relative STAT3 and mTOR mRNA expression levels,and relative STAT3,p-STAT3,mTOR,and p-mTOR protein expression levels in the Chinese medicine and combined groups after treatment were reduced(P<0.05),whereas the IL-4 and IL-10 levels increased(P<0.05).After treatment,compared to the Chinese medicine group,the combined group showed a decrease in relative STAT3,mTOR mRNA expression levels,and STAT3,p-STAT3,mTOR,and p-mTOR protein expression levels(P<0.05).Conclusion The combination of PPP and moxibustion may regulate the inflammatory mechanism of the body by inhibiting the abnormal activation of the STAT3/mTOR signaling pathway,upregulating related anti-inflammatory factor levels,downregulating pro-inflammatory factor expression,and increasing related repair factor expression,thereby promoting the recovery of atrophic gastric mucosa,reducing discomfort symptoms,and improving the physical and mental state of CAG patients with spleen and stomach weakness syndrome.
Author 李婷婷
杨琦
刘云
吴凯瑞
张艺
宋标
叶宇
李学军
裴蓓
AuthorAffiliation 安徽中医药大学研究生院 合肥 230012%安徽中医药大学第二附属医院脾胃科
AuthorAffiliation_xml – name: 安徽中医药大学研究生院 合肥 230012%安徽中医药大学第二附属医院脾胃科
Author_FL LI Tingting
LIU Yun
WU Kairui
ZHANG Yi
YE Yu
YANG Qi
LI Xuejun
SONG Biao
PEI Bei
Author_FL_xml – sequence: 1
  fullname: WU Kairui
– sequence: 2
  fullname: YE Yu
– sequence: 3
  fullname: PEI Bei
– sequence: 4
  fullname: SONG Biao
– sequence: 5
  fullname: ZHANG Yi
– sequence: 6
  fullname: LI Tingting
– sequence: 7
  fullname: YANG Qi
– sequence: 8
  fullname: LIU Yun
– sequence: 9
  fullname: LI Xuejun
Author_xml – sequence: 1
  fullname: 吴凯瑞
– sequence: 2
  fullname: 叶宇
– sequence: 3
  fullname: 裴蓓
– sequence: 4
  fullname: 宋标
– sequence: 5
  fullname: 张艺
– sequence: 6
  fullname: 李婷婷
– sequence: 7
  fullname: 杨琦
– sequence: 8
  fullname: 刘云
– sequence: 9
  fullname: 李学军
BookMark eNo9UE1LAkEAnYNBZv6LTsFu87GzM3MM6QuELnaWGXc3lFihJdJO2RpUB_EgRV6KLuEpiojNxF_j7szPSDE6vceD98FbA7mwGfoAbCBoE-GKrYZdj6LQRhC6FkaU2RhiakNsQ8RzIP-vr4JiFNUVpNwRDmRuHlRMd2riOH36zsb9WZKYziDt35jbqe4k2cePvn_Irl-yy1fT7-nJaEHiWF_1li7zOEwn7-ato4fdWfKZju_080CPvtbBSiBPIr_4hwVwtLtTKe1b5cO9g9J22YrQfIJFBeVQEiIxwkoRSTzXc5QMBCIocLlgkjkcM0dQl9UQp1wEHvN9xSWrOZhLUgCby9xzGQYyPK42mmen4byxqhoX7bbXaqnFERDPbyC_3jt1Bg
ClassificationCodes R259
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
DBID 2B.
4A8
92I
93N
PSX
TCJ
DOI 10.3969/j.issn.1006-2157.2025.02.018
DatabaseName Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitle_FL Clinical study on the treatment of chronic atrophic gastritis with spleen and stomach weakness syndrome by Piwei Peiyuan Pill combined with moxibustion
EndPage 290
ExternalDocumentID bjzyydxxb202502018
GroupedDBID -05
23N
2B.
4A8
5GY
92F
92I
93N
ABDBF
ABJNI
ACGFS
ACUHS
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CIEJG
CW9
EOJEC
OBODZ
PSX
TCJ
TGQ
U1G
U5O
ID FETCH-LOGICAL-s1058-59580a33a212bb3a3d6d4baf9131f6897a7482749567c18589fd7eeb8a7c428a3
ISSN 1006-2157
IngestDate Thu May 29 04:07:00 EDT 2025
IsPeerReviewed false
IsScholarly true
Issue 2
Keywords chronic atrophic gastritis
身心状态
炎症机制
physical and mental state
signal transducer and activator of transcription 3/mammalian target of rapamycin signaling pathway
inflammatory mechanism
信号转导和转录激活因子3/哺乳动物雷帕霉素靶蛋白信号通路
慢性萎缩性胃炎
脾胃培源丸
Piwei Peiyuan Pill
Language Chinese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-s1058-59580a33a212bb3a3d6d4baf9131f6897a7482749567c18589fd7eeb8a7c428a3
PageCount 11
ParticipantIDs wanfang_journals_bjzyydxxb202502018
PublicationCentury 2000
PublicationDate 2025-02-01
PublicationDateYYYYMMDD 2025-02-01
PublicationDate_xml – month: 02
  year: 2025
  text: 2025-02-01
  day: 01
PublicationDecade 2020
PublicationTitle 北京中医药大学学报
PublicationTitle_FL Journal of Beijing University of Traditional Chinese Medicine
PublicationYear 2025
Publisher 安徽中医药大学研究生院 合肥 230012%安徽中医药大学第二附属医院脾胃科
Publisher_xml – name: 安徽中医药大学研究生院 合肥 230012%安徽中医药大学第二附属医院脾胃科
SSID ssib058494076
ssib001103909
ssib008143994
ssj0042135
ssib051370280
Score 2.38104
Snippet R259; 目的 观察脾胃培源丸联合艾灸治疗慢性萎缩性胃炎脾胃虚弱证患者的临床疗效及其机制.方法 收集2022 年6 月—2023 年12 月就诊于安徽中医药大学第二附属医院脾胃科的慢性萎缩性胃炎脾胃虚弱证患者,将符合纳排标准的96 例患者采用随机数字表法分为对照组、中药组及联合组,每组32 例(每组各脱落2...
SourceID wanfang
SourceType Aggregation Database
StartPage 280
Title 脾胃培源丸联合艾灸治疗慢性萎缩性胃炎脾胃虚弱证的临床研究
URI https://d.wanfangdata.com.cn/periodical/bjzyydxxb202502018
Volume 48
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LaxRBEG7iBoIX8YlvAqZPYeM8ema6jz27swQhnhLILcxrFYUVTAJJTsaNoB5CDkExF8WL5CSKyBpDfk12Z36GVT29m8kDSUR2WJruqq6vq2amqoZ-EDLG45ilUehWkzBJqwwSjmqYmGmVCzeMDfiZDq53nnroTs6wB7PO7FDlaWnW0uJCNBGvnLiu5F-sCnVgV1wlewbLDjqFCiiDfeEfLAz_p7IxDTjljPqBKth4BQ4VDeoLGrjUl1QYNAACjhfSmFQwRWNQXtQIxe5hE9IAl0V9H2uES4WHNdyh0lIFg0oPuZBdcfk1KsWhJg0DOrQUzXGEwC6okAgD2H0Ta2QDAaBQifQas4IKo-ASm6ShwHso0XfLUTWS8ZpCy5Be1nQPsq6bcEQAoI6CoEYyhdZBAumWCi7Kkk7_NtSqKoBwT3EDRtBiUCbhoPGil4AeOHY1Llsxw5BtKuwyD5L6KBCGpXn0xxfL6c_X1o9Ln1wodQTUr59xeEd1pwbB8EYJBBpDWuOHbwoLdDAOaSPEFdRy_of8Wt8oEukLsbywL2qz1I9GdNKd42G3xbFr2pHilyoIJ72yp2W89Eaxym6zOM1LR2BWcYDsUeduC1co544CJgYCJtAuat9d7cgPb58ePVlZXk6WliIkg9zI5OfIsAU5pVUhw9Kv-42D7AGnRZR2s-MmJusDd-WYtlfe6ghCd8EMjOaLwI9ZxXm-A2QjZEzDvv830Gq5YKsZth6VItvpi-SCTklHZfF-uUSGVh5fJiNTetLNFTKdr-3l7Xb346_ezsZ-p5OvbnY3Xudv9rLVTu_77-zd-96rz70XX_KN9Wx3GwvtdvZyveDKP2x1d7_lX1ezrbX9zo_uztvs02a2_fMqmWkE07XJqj6MpToPKRivOsLhRmjbIcS6UWSHduImLAqbwrTNpsuFF3q4ozB-b_FiSAK4aCZemkY89GJm8dC-RiqtZ630OhlNIzxWInbMNEoYj-LQZCyBCDox7RSncN4g97RC5vTLdn7uuBlvnorqFjl_8NzeJpWF54vpHUgjFqK72vx_AAxe11g
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E8%84%BE%E8%83%83%E5%9F%B9%E6%BA%90%E4%B8%B8%E8%81%94%E5%90%88%E8%89%BE%E7%81%B8%E6%B2%BB%E7%96%97%E6%85%A2%E6%80%A7%E8%90%8E%E7%BC%A9%E6%80%A7%E8%83%83%E7%82%8E%E8%84%BE%E8%83%83%E8%99%9A%E5%BC%B1%E8%AF%81%E7%9A%84%E4%B8%B4%E5%BA%8A%E7%A0%94%E7%A9%B6&rft.jtitle=%E5%8C%97%E4%BA%AC%E4%B8%AD%E5%8C%BB%E8%8D%AF%E5%A4%A7%E5%AD%A6%E5%AD%A6%E6%8A%A5&rft.au=%E5%90%B4%E5%87%AF%E7%91%9E&rft.au=%E5%8F%B6%E5%AE%87&rft.au=%E8%A3%B4%E8%93%93&rft.au=%E5%AE%8B%E6%A0%87&rft.date=2025-02-01&rft.pub=%E5%AE%89%E5%BE%BD%E4%B8%AD%E5%8C%BB%E8%8D%AF%E5%A4%A7%E5%AD%A6%E7%A0%94%E7%A9%B6%E7%94%9F%E9%99%A2+%E5%90%88%E8%82%A5+230012%25%E5%AE%89%E5%BE%BD%E4%B8%AD%E5%8C%BB%E8%8D%AF%E5%A4%A7%E5%AD%A6%E7%AC%AC%E4%BA%8C%E9%99%84%E5%B1%9E%E5%8C%BB%E9%99%A2%E8%84%BE%E8%83%83%E7%A7%91&rft.issn=1006-2157&rft.volume=48&rft.issue=2&rft.spage=280&rft.epage=290&rft_id=info:doi/10.3969%2Fj.issn.1006-2157.2025.02.018&rft.externalDocID=bjzyydxxb202502018
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fbjzyydxxb%2Fbjzyydxxb.jpg